Takeda Seeks To Double Foreign OTC Business To $38 Million By 2017
This article was originally published in PharmAsia News
Takeda Pharmaceutical seeks to double overseas sales of over-the-counter drugs over the next three years to help make up for a contracting market in a Japan of fewer buyers and falling prices.
You may also be interested in...
HBW Insight speaks to new Global Self-Care Federation chair and Bayer CH chief Heiko Schipper about the role that self-care can play in alleviating pressure on national health care systems, the importance of self-care's scientific credentials and of maintaining supply chain continuity during the coronavirus pandemic.
Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.